- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Happiness.
Displaying page 1 of 1.
EudraCT Number: 2022-003670-22 | Sponsor Protocol Number: IIBSP-OXI-2022-124 | Start Date*: 2023-07-31 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Controlled and randomized clinical trial to evaluate the efficacy of the combination of oxytocin plus self-compassion training in patients with Borderline Personality Disorder | ||
Medical condition: Borderline personality disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004294-48 | Sponsor Protocol Number: 20200106 | Start Date*: 2021-07-07 |
Sponsor Name:Amsterdam UMC, location VUmc | ||
Full Title: Glioma: Reducing Anxiety by conSuming cannabinoidS – GRASS study. Treating anxiety with CBD in glioma patients – A randomized-controlled trial | ||
Medical condition: Primary brain tumor patients with anxiety symptoms | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003195-68 | Sponsor Protocol Number: 2015-003195-68 | Start Date*: 2015-11-11 | |||||||||||
Sponsor Name:The Newcastle upon Tyne NHS Hospitals Foundation Trust | |||||||||||||
Full Title: Observational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy. | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001829-40 | Sponsor Protocol Number: 201 | Start Date*: 2019-01-02 | |||||||||||
Sponsor Name:Y-mAbs Therapeutics A/S | |||||||||||||
Full Title: A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete... | |||||||||||||
Medical condition: Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
